Source-grounded facts extracted from Onconetix, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Onconetix, Inc.: Amended charter to effect a 1-for-10 reverse stock split of common stock, effective May 21, 2026 (effective 2026-05-21).
“On May 20, 2026, the Company expects to file an amendment to its Charter with the Secretary of State of the State of Delaware (the “Amendment”) to effect the Reverse Stock Split.”
Onconetix, Inc. shareholders approved Approval of the adjournment of the Special Meeting, if necessary or appropriate, to solicit additional proxies if there are insufficient votes at the time of the Special Meeting to approve the Reverse Stock Split Proposal. at the 2026-04-30 meeting.
“2. The Adjournment Proposal. The votes were cast for this matter as follows: Votes For Votes Against Abstentions 1,332,088 223,071 1,530”
Onconetix, Inc. shareholders approved Approval of an amendment to the Company's Amended and Restated Certificate of Incorporation to effect one or more reverse stock splits of all of the outstanding shares of the Company's common stock, par value $0.00001 per share, at a ratio in the range of 1-for-2 to 1-for-10, at any time prior to th at the 2026-04-30 meeting.
“1. Reverse Stock Split Proposal The votes were cast for this matter as follows: Votes For Votes Against Abstentions 1,301,918 253,378 1,393”
Onconetix, Inc.: Onconetix, Inc. filed an amendment to its Amended and Restated Certificate of Incorporation to effect a 1-for-5 reverse stock split, effective March 25, 2026 (effective 2026-03-25).
“On March 24, 2026, the Company filed the Amendment to its Charter with the Secretary of State of the State of Delaware to effect the Reverse Stock Split.”
Onconetix, Inc. entered into Share Exchange Agreement with Realbotix Corp., Simulacra Corporation, and Realbotix, LLC (effective 2026-02-11).
“On February 11, 2026, Onconetix, Inc, a Delaware corporation (“ Onconetix ” or “ Buyer ”), entered into a Share Exchange Agreement (the “ Share Exchange Agreement ”), by and among (i) Onconetix, (ii) Realbotix Corp., a company existing under the laws of the Province of Ontario (“ Parent ”), (iii) Simulacra Corporation, a Delaware corporation and a wholly-owned subsidiary of Parent (the “ Seller ”) and (iv) Realbotix, LLC, a Delaware limited liability company and wholly owned subsidiary of the Seller (the “ Company ” or “ Realbotix ”).”
Onconetix, Inc. amended Amendment with Laboratory Corporation of America Holdings (Labcorp) (effective 2025-12-06).
“On December 6, 2025, Proteomedix AG, a Swiss Company (“Proteomedix”), a wholly-owned subsiairy of Onconetix, Inc. (the “Company”), entered into an amendment (the “Amendment”) of the license agreement with Laboratory Corporation of America Holdings (“Labcorp”) dated as of March 27, 2023, by and between the Company and Labcorp (the “Agreement”), pursuant to which Labcorp has the exclusive right to develop and commercialize Proclarix and other products developed by Labcorp using Proteomedix’s intellectual property covered by the license in the United States (the “Licensed Products”).”
Onconetix, Inc. issued warrants to purchase 2,025,223 shares of Common Stock of warrant to institutional investors for aggregate purchase price of approximately $6.25 million.
“On October 1, 2025, Onconetix, Inc., a Delaware corporation (the “ Company ”), entered into, and sold to institutional investor(s) (collectively, the “ PIPE Investors ”), pursuant to a securities purchase agreement (the “ Securities Purchase Agreement ”) an aggregate of 7,813 shares of Series E convertible preferred stock, par value $0.00001 per share (“ Series E Preferred Stock ”), which are convertible into common stock of the Company, $0.00001 par value per share (the “ Common Stock ”) and warrants to purchase 2,025,223 shares of Common Stock (the “ Warrants ” and, together with the Series E Preferred Stock, the “ PIPE Securities ”), for an aggregate purchase price of approximately $6.25 million.”
Onconetix, Inc. issued 7,813 shares of Series E convertible preferred stock of preferred stock to institutional investors for aggregate purchase price of approximately $6.25 million.
“On October 1, 2025, Onconetix, Inc., a Delaware corporation (the “ Company ”), entered into, and sold to institutional investor(s) (collectively, the “ PIPE Investors ”), pursuant to a securities purchase agreement (the “ Securities Purchase Agreement ”) an aggregate of 7,813 shares of Series E convertible preferred stock, par value $0.00001 per share (“ Series E Preferred Stock ”), which are convertible into common stock of the Company, $0.00001 par value per share (the “ Common Stock ”) and warrants to purchase 2,025,223 shares of Common Stock (the “ Warrants ” and, together with the Series E Preferred Stock, the “ PIPE Securities ”), for an aggregate purchase price of approximately $6.25 million.”
Onconetix, Inc. issued warrants to purchase 4,362,827 shares of Common Stock of warrant to eleven institutional investors for included in aggregate purchase price of approximately $12.9 million.
“On September 22, 2025, Onconetix, Inc., a Delaware corporation (the “ Company ”), entered into, and sold to eleven institutional investor(s) (collectively, the “ PIPE Investors ”), pursuant to a securities purchase agreement (the “ Securities Purchase Agreement ”) an aggregate of 16,099 shares of Series D convertible preferred stock, par value $0.00001 per share (“ Series D Preferred Stock ”), which are convertible into common stock of the Company, $0.00001 par value per share (the “ Common Stock ”), which includes an issuance of 500 shares of Series D Preferred Stock to a certain investor as consideration for the PIPE Investors’ irrevocable commitment to purchase shares of the Series D Preferred Stock, and warrants to purchase 4,362,827 shares of Common Stock (the “ Warrants ” and, together with the Series D Preferred Stock, the “ PIPE Securities ”), for an aggregate purchase price of approximately $12.9 million.”
Onconetix, Inc. issued 16,099 shares of Series D convertible preferred stock of preferred stock to eleven institutional investors for aggregate purchase price of approximately $12.9 million of which approximately $9.3 million was paid in cash and the balance was used to offset certain amounts.
“On September 22, 2025, Onconetix, Inc., a Delaware corporation (the “ Company ”), entered into, and sold to eleven institutional investor(s) (collectively, the “ PIPE Investors ”), pursuant to a securities purchase agreement (the “ Securities Purchase Agreement ”) an aggregate of 16,099 shares of Series D convertible preferred stock, par value $0.00001 per share (“ Series D Preferred Stock ”), which are convertible into common stock of the Company, $0.00001 par value per share (the “ Common Stock ”), which includes an issuance of 500 shares of Series D Preferred Stock to a certain investor as consideration for the PIPE Investors’ irrevocable commitment to purchase shares of the Series D Preferred Stock, and warrants to purchase 4,362,827 shares of Common Stock (the “ Warrants ” and, together with the Series D Preferred Stock, the “ PIPE Securities ”), for an aggregate purchase price of approximately $12.9 million.”
Onconetix, Inc. amended loan of aggregate principal amount of $5.2 million with Veru Inc. maturing September 19, 2025.
“On August 28, 2025, Veru and the Company agreed to amend and restate the September Veru Note (as amended and restated, the “ Second A&R September Veru Note ”). Pursuant to the Second A&R September Veru Note, the principal amount owed to Veru was increased by $100,000 to an aggregate principal amount of $5.2 million, and the maturity date was amended to September 19, 2025.”
Onconetix, Inc. incurred loan of principal amount of $58,823.53 with KCP Fund I, LLC maturing upon the earlier of (i) the Company's receipt of sufficient proceeds from its equity line of credit with Keystone ... and (ii) May 28, 2026.
“(ii) KCP Fund I, LLC, an affiliate of Keystone (the “ KCP Note ”, and together with the Keystone Note, the “ Notes ”) each with original issue discount of $8,823.53 and a principal amount of $58,823.53”
Onconetix, Inc. incurred loan of principal amount of $58,823.53 with Keystone Capital Partners, LLC maturing upon the earlier of (i) the Company's receipt of sufficient proceeds from its equity line of credit with Keystone ... and (ii) May 28, 2026.
“I, LLC, an affiliate of Keystone (the “ KCP Note ”, and together with the Keystone Note, the “ Notes ”) each with original issue discount of $8,823.53 and a principal amount of $58,823.53. The Notes are due and payable upon the earlier of (i) the Company’s receipt of sufficient proceeds from its equity line of credit with Keystone (the “ ELOC ”) and (ii) May 28,”
Onconetix, Inc. amended debt of principal amount owed to Veru was increased by $100,000 to an aggregate principal amount of $5.1 million with Veru Inc. at non-interest bearing maturing maturity date was amended to August 14, 2025.
“the September Veru Note (as amended and restated, the “ A&R September Veru Note ”). Pursuant to the A&R September Veru Note, the principal amount owed to Veru was increased by $100,000 to an aggregate principal amount of $5.1 million, and the maturity date was amended to August 14, 2025. All other terms of the September Veru Note remained the same. The above”
Onconetix, Inc. incurred loan of aggregate principal amount of $117,647.06 with Keystone Capital Partners, LLC at does not initially bear interest...any amounts due which are not paid when due s maturing due and payable upon the earlier of (i) the Company's receipt of sufficient proceeds from its equity line of credit with Keystone and (ii) March 6, 2026.
“On August 6, 2025, Onconetix, Inc. (the “ Company ”) issued a promissory note (the “ Keystone Note” ) to Keystone Capital Partners, LLC (“ Keystone ”) with original issue discount of $17,647.06, in an aggregate principal amount of $117,647.06.”
Onconetix, Inc. incurred loan of aggregate principal amount of $147,058.82 with Keystone Capital Partners, LLC at does not initially bear interest maturing March 5, 2026.
“issued a promissory note to Keystone Capital Partners, LLC with original issue discount of $22,058.82, in an aggregate principal amount of $147,058.82. The note is due and payable upon the earlier of (i) the Company’s receipt of sufficient proceeds from the ELOC and (ii) March 5, 2026”
Onconetix, Inc.: Amendment to Amended and Restated Certificate of Incorporation to effect a 1-for-85 reverse stock split (effective 2025-06-13).
“On June 11, 2025, the Company expects to file the Amendment to its Charter with the Secretary of State of the State of Delaware to effect a reverse stock split of its Common Stock at a ratio of 1-to-85 (the "Reverse Stock Split"). The Reverse Stock Split will become effective in accordance with the terms of the Amendment at 12:01 a.m. Eastern Time on June 13, 2025 (the "Effective Time").”
Onconetix, Inc. received a nasdaq deficiency notice notice regarding late filing (rules 5250(c)(1)).
“May 20, 2025, Onconetix, Inc. (the “ Company ”) received a deficiency notice (the “ Notice ”) from the Nasdaq Stock Market LLC (“ Nasdaq ”) that the Company was not in compliance with Nasdaq’s continued listing standards (the “ Listing Rules ”) as set forth in Listing Rule 5250(c)(1) given the Company’s failure to timely file its Quarterly Report on Form 10-Q for the three months ended March 31, 2025 (the “ 10-Q ”), and that this matter serves as an additional basis for delisting the Company’s securities from Nasdaq. As previously reported in the Current Report on Form 8-K filed with the Secur”
Onconetix, Inc. received a nasdaq deficiency notice notice regarding late filing (rules 5250(c)(1)).
“April 24, 2025, Onconetix, Inc. (the “ Company ”) received a deficiency notice (the “ Notice ”) from the Nasdaq Stock Market LLC (“ Nasdaq ”) that the Company was not in compliance with Nasdaq’s continued listing standards (the “ Listing Rules ”) as set forth in Listing Rule 5250(c)(1) given the Company’s failure to timely file its Annual Report on Form 10-K for the fiscal year ended December 31, 2024 (the “ 10-K ”), and that this matter serves as an additional basis for delisting the Company’s securities from Nasdaq. As previously reported in the Current Report on Form 8-K filed with the Secu”
Onconetix, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A), 5810(c)(3)(A)(iii)).
“April 14, 2025, Nasdaq issued a further notice (the “Notice”) to the Company that it determined that the Company’s securities had a closing bid price of $0.10 or less for ten consecutive trading days. Accordingly, the Company is subject to the provisions under Nasdaq Listing Rule 5810(c)(3)(A)(iii). As a result, unless the Company timely requests a hearing before the Nasdaq Hearings Panel (the “Panel”), trading of the Common Stock will be suspended at the opening of business on April 23, 2025, and a Form 25-NSE will be filed with the Commission, which will remove the Company’s securities from”
Karina Fedasz was appointed as Interim Chief Executive Officer at Onconetix, Inc..
“On April 2, 2025, the Company appointed Karina Fedasz, 52, the Company’s Interim Chief Financial Officer, as Interim Chief Executive Officer of the Company, effective immediately.”
James Sapirstein resigned as Executive Chairman at Onconetix, Inc..
“Effective as of March 28, 2025, James Sapirstein resigned as Executive Chairman and a member of the Board of Directors (the “Board”) of Onconetix, Inc. (the “Company”).”
Andrew Oakley was appointed as Class II director at Onconetix, Inc..
“On February 24, 2025, the Board approved an increase to the Board’s size from five to six members and appointed Andrew Oakley, 62, to fill the new Board seat as a Class II director”
James Sapirstein was appointed as Executive Chairman at Onconetix, Inc..
“On February 24, 2025, the Company’s Board of Directors (the “Board”) appointed James Sapirstein, 63, an existing member of the Board, as Executive Chairman.”
Ralph Schiess resigned as Interim Chief Executive Officer and Chief Science Officer at Onconetix, Inc..
“On February 24, 2025, Dr. Ralph Schiess resigned from his positions as the Interim Chief Executive Officer and Chief Science Officer of Onconetix, Inc. (the “Company”), effective immediately”
Christian Brühlmann resigned as Chief Strategy Officer at Onconetix, Inc..
“On February 18, 2025, Christian Brühlmann resigned from his position as Chief Strategy Officer of the Company.”
Onconetix, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).
“January 23, 2025, Onconetix, Inc. (the “Company”) received a letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, based upon the closing bid price of the Company’s common stock, par value $0.00001 per share (“Common Stock”), from November 25, 2024 to January 10, 2025, the Company is no longer in compliance with the requirement for continued listing on The Nasdaq Capital Market to maintain a minimum bid price of $1.00 per share, as set forth in Nasdaq Listing Rule 5550(a)(2) (the “Notice”). The Notice has no immediate effect on the continued li”
Onconetix, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).
“January 23, 2025, Onconetix, Inc. (the “Company”) received a letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, based upon the closing bid price of the Company’s commo”
Onconetix, Inc. received a nasdaq deficiency notice notice regarding late filing (rules 5250(c)(1)).
“December 6, 2024, Onconetix, Inc. (the “Company”) received a letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC informing the Company that, as a result of not having timely filed its Quarterly Report on Form 10-Q for the period ended September 30, 2024 (the “Form 10-Q”) with the Securities and Exchange Commission (the “SEC”), the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1), which requires listed companies to timely file all required periodic financial reports with the SEC. On December 10, 2024, the Company filed its Form 10-Q with the SEC. This Cur”
EisnerAmper LLP resigned as auditor of Onconetix, Inc..
“On October 15, 2024, EisnerAmper LLP (“EA”) submitted its resignation as Onconetix, Inc.’s (the “Company”) independent registered public accounting firm, effective upon the Company’s upcoming filing of its Quarterly Report on Form 10-Q for the quarter ended September 30, 2024.”
Onconetix, Inc.: Amended Certificate of Incorporation to effect a 1-for-40 reverse stock split of common stock (effective 2024-09-24).
“On September 23, 2024, the Company filed an amendment (the “ Amendment ”) to the Company’s Amended and Restated Certificate of Incorporation to effect a Reverse Stock Split of all of the outstanding shares of its issued and outstanding Common Stock at a ratio of one-for-forty (1:40). The Reverse Stock Split became effective in accordance with the terms of the Amendment at 12:01 a.m. Eastern Time on September 24, 2024 (the “ Effective Time ”).”
Karina Fedasz was appointed as Interim Chief Financial Officer at Onconetix, Inc..
“In connection with Ms. Fedasz’s appointment as Interim Chief Financial Officer, on June 10, 2024, the Company and Ms. Fedasz entered into a consulting agreement (the “ Fedasz Consulting Agreement ”), pursuant to which Ms. Fedasz will serve as Interim Chief Financial Officer of the Company and will be paid $15,000 per month for up to 80 hours of monthly service to the Company and will provide signatory services for $2,500 per month.”
Karina M. Fedasz was appointed as Interim Chief Financial Officer at Onconetix, Inc..
“On June 10, 2024, the Company appointed Karina M. Fedasz, 51, as Interim Chief Financial Officer of the Company, effective immediately.”
Bruce Harmon resigned as Chief Financial Officer at Onconetix, Inc..
“On June 8, 2024, Bruce Harmon resigned as Chief Financial Officer of Onconetix, Inc. (the “ Company ”), effective immediately.”
Onconetix, Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).
“equity for the fiscal year ended December 31, 2023 as reported in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission on April 1, 2024 was $1,404,476, and as of the date of the Notice, the Company did not meet the alternatives to the Minimum Stockholders’ Equity Requirement of having either (i) a market value of listed”
Onconetix, Inc. amended Altos Amendment with Altos Ventures (effective 2024-04-24).
“On April 24, 2024, the Debenture was amended to extend the maturity date to the earlier of (i) the closing under the Subscription Agreement and (ii) October 31, 2024 (the "Altos Amendment").”
Onconetix, Inc. entered into Forbearance Agreement with Veru Inc. (effective 2024-04-24).
“(the “Company”) entered into an asset purchase agreement with Veru Inc., a Wisconsin corporation (“Veru”) (the “Veru APA”). Pursuant to the terms of the Veru APA, the Company agreed to provide Veru”
Onconetix, Inc. completed an acquisition involving Proteomedix AG for share exchange (closed 2023-12-15).
“the Company consummated a share exchange transaction (the “ Share Exchange ”) with Proteomedix on December 15, 2023.”
Ajit Singh was appointed as Director at Onconetix, Inc..
“On February 8, 2024, the Board of Directors (the “ Board ”) of the Company appointed Ajit Singh to fill the vacancy created by the resignation of Neil Campbell.”
Neil Campbell resigned as Director at Onconetix, Inc..
“On February 8, 2024, the Board of Directors (the “ Board ”) of the Company appointed Ajit Singh to fill the vacancy created by the resignation of Neil Campbell.”
Thomas Meier was appointed as Director at Onconetix, Inc..
“On February 6, 2024, pursuant to the Certificate of Designation of Series B Convertible Preferred Stock, the holders of Series B Convertible Preferred Stock appointed Thomas Meier, PhD, to the board of directors of Onconetix, Inc. (the “ Company ”).”
Erin Henderson resigned as Chief Business Officer at Onconetix, Inc..
“Erin Henderson resigned as Chief Business Officer of Onconetix, Inc. (the “Company”), effective as of December 21, 2023.”
James Sapirstein was appointed as Lead Independent Director at Onconetix, Inc..
“Also on January 12, 2024, the Board appointed James Sapirstein, the current Non-Executive Chairman of the Board, to serve as Lead Independent Director pending the Board’s appointment of a permanent chief executive officer.”
Dr. Ralph Schiess was appointed as Interim Chief Executive Officer at Onconetix, Inc..
“On January 12, 2024, the Board appointed Dr. Ralph Schiess, the Company’s Chief Science Officer, to serve as the Company’s Interim Chief Executive Officer.”
Dr. Neil Campbell resigned as President and Chief Executive Officer at Onconetix, Inc..
“Effective as of January 10, 2024, Dr. Neil Campbell resigned as President and Chief Executive Officer and a member of the Board of Directors (the “Board”) of Onconetix, Inc. (the “Company”).”
Erin Henderson resigned as Chief Business Officer at Onconetix, Inc..
“On and effective December 21, 2023, Erin Henderson resigned as Chief Business Officer of Onconetix, Inc. (the “Company”) to pursue other opportunities.”
Onconetix, Inc. entered into Share Exchange Agreement with Proteomedix AG valued at Aggregate value of Exchange Shares at Closing approximately $75,000,000; Onconetix issued 3,675,414 (effective 2023-12-15).
“On December 15, 2023, Onconetix, Inc, a Delaware corporation f/k/a Blue Water Biotech, Inc. (“ Onconetix ” or the “ Buyer ”), entered into a Share Exchange Agreement”
Onconetix, Inc.: Amended bylaws to reflect the name change to Onconetix, Inc (effective 2023-12-15).
“On December 1, 2023, the Board approved the Name Change and an amendment to the Company’s bylaws to reflect the Name Change, effective as of the Closing Date on December 15, 2023. No other changes were made to the bylaws.”
Onconetix, Inc.: Amended articles of incorporation to change company name from Blue Water Biotech, Inc. to Onconetix, Inc (effective 2023-12-15).
“On December 15, 2023, Onconetix filed a Certificate of Amendment to its Amended and Restated Articles of Incorporation with the Delaware Secretary of State (the “ Amendment ”). The Amendment changed the name of Onconetix from “Blue Water Biotech, Inc.” to “Onconetix, Inc.,” effective immediately (the “ Name Change ”).”
Onconetix, Inc. entered into Share Exchange Agreement with Proteomedix AG, the Sellers, and the Sellers’ Representative valued at $75,000,000 (effective 2023-12-15).
“On December 15, 2023, Onconetix, Inc, a Delaware corporation f/k/a Blue Water Biotech, Inc. (“ Onconetix ” or the “ Buyer ”), entered into a Share Exchange Agreement (the “ Share Exchange Agreement ”), by and among (i) Onconetix, (ii) Proteomedix AG, a Swiss Company (“ Proteomedix ” or the “ Company ”), (iii) each of the holders of outstanding capital stock or Company Convertible Securities (other than Company Stock Options) named therein (collectively, the “ Sellers ”) and (iv) Thomas Meier, in the capacity as the representative of Sellers in accordance with the terms and conditions of the Share Exchange Agreement (the “ Sellers’ Representative ”).”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.